NASDAQ$INGN
Inogen Inc · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Inogen's financial performance declined slightly in Q1 2020 due to decreased direct-to-consumer sales and lower gross margins, but was partially offset by growth in domestic and international business-to-business sales.
Inogen reported a slight decrease in total revenue for Q1 2020, with a net loss of $1.6 million. The company experienced growth in domestic and international business-to-business sales, but a decline in direct-to-consumer sales. Gross margins also decreased due to manufacturing inefficiencies and product sales mix. The company withdrew its 2020 guidance due to the uncertainty surrounding the impact of the COVID-19 pandemic.
- Total revenue decreased by 1.9% to $88.5 million compared to Q1 2019.
- Domestic business-to-business sales increased by 5.7% to $27.6 million year-over-year.
- Direct-to-consumer sales declined by 8.9% to $35.5 million compared to the same period in 2019.
- The company withdrew its full year 2020 guidance due to the uncertainty around the impact of the COVID-19 pandemic.
Headline financials
Revenue & EPS history
Inogen · Revenue · Quarterly
$88.5M
Forward guidance
Inogen withdrew its previously announced full year 2020 guidance issued on February 25, 2020 as the Company is unable to estimate the scope, duration, and impact of the COVID-19 PHE for full year 2020.
Tailwinds
- Implementing cost savings by delaying certain personnel hires.
- Reducing advertising spend.
- Increasing rental setups to improve lead utilization.
- The company believes it could continue to see a decline in sales in its direct-to-consumer channel until patient mobility and consumer confidence increases.
- Increase in demand that it experienced for its products in the first quarter in its business-to-business channels due to the COVID-19 PHE may be limited or demand may decline in the future as new COPD patient referrals could decline as physician offices are limiting patient interactions.
Headwinds
- The Company believes it could continue to see a decline in sales in its direct-to-consumer channel until patient mobility and consumer confidence increases.
- The Company also believes the increase in demand that it experienced for its products in the first quarter in its business-to-business channels due to the COVID-19 PHE may be limited or demand may decline in the future as new COPD patient referrals could decline as physician offices are limiting patient interactions.
- Given the increased uncertainty around the scope, duration, and impact of the COVID-19 PHE as well as revenue mix between direct-to-consumer and business-to-business channels, Inogen cannot estimate the overall impact to its operations and financial results, which could be material.
- Uncertainty regarding, and the potential variability of, the amounts of interest income, interest expense, depreciation and amortization, stock-based compensation, provision for income taxes, and certain other infrequently occurring items, such as acquisition-related costs, that may be incurred in the future.
- The company is unable to estimate the scope, duration, and impact of the COVID-19 PHE for full year 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-0.7%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-2.0%
Avg return
30 days after
49%
26 / 53 earnings
Positive
+35.5%
Q2 2024
Best reaction
-32.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.4% | -5.3% | -11.0% | |
| Q4 2025 | +4.3% | +5.8% | +6.0% | |
| Q3 2025 | -0.6% | +0.9% | -1.3% | |
| Q1 2025 | -11.5% | -14.4% | -8.1% | |
| Q4 2024 | -14.8% | -14.6% | -28.6% | |
| Q3 2024 | +15.9% | +9.1% | -0.7% | |
| Q2 2024 | +35.5% | +50.6% | +43.0% | |
| Q1 2024 | +14.6% | +17.7% | +17.7% | |
| Q4 2023 | -32.2% | -24.3% | -13.0% | |
| Q3 2023 | -1.3% | -8.1% | +10.0% | |
| Q2 2023 | -14.6% | -18.7% | -20.8% | |
| Q1 2023 | -6.1% | -19.3% | -21.9% | |
| Q4 2022 | -31.4% | -32.4% | -46.4% | |
| Q3 2022 | -12.5% | -10.0% | -0.8% | |
| Q2 2022 | -6.9% | -7.3% | -6.3% | |
| Q1 2022 | -2.2% | -7.8% | +2.0% | |
| Q4 2021 | +12.6% | +25.3% | +13.5% | |
| Q3 2021 | -6.0% | -7.3% | -21.6% | |
| Q2 2021 | -22.8% | -16.8% | -22.1% | |
| Q1 2021 | -3.5% | -2.4% | -12.8% | |
| Q4 2020 | +4.6% | +5.4% | -4.2% | |
| Q3 2020 | -7.1% | +9.8% | +33.0% | |
| Q2 2020 | +16.4% | +17.0% | -6.5% | |
| Q1 2020 | -21.4% | -20.1% | -24.2% | |
| Q4 2019 | +10.2% | +5.4% | +26.4% | |
| Q3 2019 | +17.3% | +19.7% | +24.4% | |
| Q2 2019 | -15.4% | -18.5% | -20.9% | |
| Q1 2019 | -28.8% | -22.2% | -31.8% | |
| Q4 2018 | -26.4% | -25.9% | -35.1% | |
| Q3 2018 | -18.8% | -22.6% | -24.8% | |
| Q2 2018 | +7.7% | +6.3% | +21.3% | |
| Q1 2018 | +21.0% | +18.7% | +26.7% | |
| Q4 2017 | -9.3% | -8.4% | -7.8% | |
| Q3 2017 | +16.1% | +12.9% | +15.0% | |
| Q2 2017 | -5.6% | -3.9% | +0.3% | |
| Q1 2017 | +0.2% | -2.6% | +11.9% | |
| Q4 2016 | +6.8% | +6.0% | +11.4% | |
| Q3 2016 | +13.0% | +15.8% | +22.3% | |
| Q2 2016 | +0.9% | +9.3% | +8.9% | |
| Q1 2016 | -6.6% | — | — | |
| Q4 2015 | +20.6% | — | — | |
| Q3 2015 | -1.8% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +4.9% | — | — | |
| Q4 2014 | +1.8% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2013 | -1.7% | — | — | |
| Q3 2014 | +6.0% | — | — | |
| Q2 2014 | +3.6% | — | — | |
| Q2 2013 | +3.6% | — | — | |
| Q1 2013 | +12.7% | — | — | |
| Q1 2014 | +12.7% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro